Key Highlights

● Gilead posted Earnings of $2.55 a share against $2.21 expected.

● Revenue reached $8.30 billion, above the $7.81 billion consensus.

● The base Business outlook was raised for the third time this year.

● PrEP sales, including Yeztugo, nearly doubled from a year earlier.

Gilead Sciences (NASDAQ:GILD) beat on profit and Revenue and lifted its outlook once again, keeping its shares steady to higher in extended trading on Thursday.

Beating the numbers

Gilead Sciences rounded out a strong day for drugmakers with a solid report after the close on October 29. The biotech giant posted earnings of $2.55 a share, well ahead of the $2.21 analysts expected. Revenue reached $8.30 billion, comfortably above the $7.81 billion consensus.

The reaction in extended trading was steady rather than spectacular. One source showed the shares modestly higher after hours, while a headline from another said the shares stayed flat. Either way, the stock held its ground on an evening when several other big names stumbled.

Third time's the charm

The standout detail was the guidance. Gilead raised its full-year outlook for its base business for the third time this year, a pattern that signals consistent momentum rather than a one-off beat. Chief executive Daniel O'Day said the total increase now stands at "$1.6 billion since the start of 2026," according to media reports.

Repeated raises matter because they build credibility. A record of raised forecasts can build credibility over time and make investors more comfortable paying up for future earnings.

HIV still the engine

Gilead's HIV Franchise drove much of the growth. Sales in the category rose solidly from a year earlier, and its PrEP business, which includes the prevention drug Yeztugo, nearly doubled. Pre-exposure prophylaxis treatments help prevent HIV infection, and their growth has become a key pillar of Gilead's long-term story.

The company's results added to a broader picture of strength in large-cap pharma. Earlier on Thursday, Eli Lilly (NYSE:LLY) closed at an all-time high of $1,373.70 after raising its revenue guidance, and Merck (NYSE:MRK) beat estimates and lifted its profit forecast.

Health care in the driver's seat

Health care was the best-performing sector in the S&P 500 during the regular session. The group benefited from a rotation away from mega-cap technology after Alphabet (NASDAQ:GOOGL)'s worst day since its 2004 IPO, which erased about $500 billion of market value.

"Money is rotating within the market rather than leaving it," one market strategist said, according to market commentary.

The headline indexes masked the breadth of the advance. The S&P 500 slipped 23.59 points to 7,720.39 and the Nasdaq Composite tumbled 365.13 points to 26,184.72, yet more than 400 S&P 500 members rose. The Russell 2000 climbed 28.71 points to 2,859.22.

A tough evening elsewhere

Gilead's stability contrasted with turbulence across the after-hours tape. Amazon (NASDAQ:AMZN) and Intel (NASDAQ:INTC) both fell sharply after reporting, pushing Nasdaq-100 futures lower. Stryker (NYSE:SYK) tumbled after missing estimates, and Reddit (NYSE:RDDT), Roblox (NYSE:RBLX) and Twilio (NYSE:TWLO) each slid sharply.

Macro data added a hawkish backdrop. Third-quarter GDP grew faster than forecast, and September PCE Inflation ran hot, keeping traders focused on a possible December rate hike from the Federal Reserve, which held steady on Wednesday in a 10-2 vote.

What to watch

Friday's regular session will show whether Gilead's after-hours steadiness turns into a real gain. Investors will dig into the details behind the third guidance raise and the trajectory of the PrEP business heading into 2027.

AbbVie (NYSE:ABBV) reports on Friday, giving another read on the pharma sector's momentum. The third-quarter Employment Cost index also arrives that morning, and the Fed's December 8 to 9 meeting remains a key risk for the broader market. For Gilead, the question is whether a fourth raise is still possible before the year is out.